» Articles » PMID: 24842054

Protease Activated Receptor-1 Deficiency Diminishes Bleomycin-induced Skin Fibrosis

Overview
Journal Mol Med
Publisher Biomed Central
Date 2014 May 21
PMID 24842054
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulating evidence shows that protease-activated receptor-1 (PAR-1) plays an important role in the development of fibrosis, including lung fibrosis. However, whether PAR-1 also plays a role in the development of skin fibrosis remains elusive. The aim of this study was to determine the role of PAR-1 in the development of skin fibrosis. To explore possible mechanisms by which PAR-1 could play a role, human dermal fibroblasts and keratinocytes were stimulated with specific PAR-1 agonists or antagonists. To investigate the role of PAR-1 in skin fibrosis, we subjected wild-type and PAR-1-deficient mice to a model of bleomycin-induced skin fibrosis. PAR-1 activation leads to increased proliferation and extra cellular matrix (ECM) production, but not migration of human dermal fibroblasts (HDF) in vitro. Moreover, transforming growth factor (TGF)-β production was increased in keratinocytes upon PAR-1 activation, but not in HDF. The loss of PAR-1 in vivo significantly attenuated bleomycin-induced skin fibrosis. The bleomycin-induced increase in dermal thickness and ECM production was reduced significantly in PAR-1-deficient mice compared with wild-type mice. Moreover, TGF-β expression and the number of proliferating fibroblasts were reduced in PAR-1-deficient mice although the difference did not reach statistical significance. This study demonstrates that PAR-1 contributes to the development of skin fibrosis and we suggest that PAR-1 potentiates the fibrotic response mainly by inducing fibroblast proliferation and ECM production.

Citing Articles

Activated Protein C Protects against Murine Contact Dermatitis by Suppressing Protease-Activated Receptor 2.

Xue M, Lin H, Zhao R, Fryer C, March L, Jackson C Int J Mol Sci. 2022; 23(1).

PMID: 35008942 PMC: 8745259. DOI: 10.3390/ijms23010516.


Hirudin Ameliorates Renal Interstitial Fibrosis via Regulating TGF-1/Smad and NF-B Signaling in UUO Rat Model.

Yang K, Fan B, Zhao Q, Ji Y, Liu P, Gao S Evid Based Complement Alternat Med. 2020; 2020:7291075.

PMID: 32714415 PMC: 7336220. DOI: 10.1155/2020/7291075.


Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch.

Kahremany S, Hofmann L, Gruzman A, Cohen G Int J Mol Sci. 2020; 21(14).

PMID: 32664385 PMC: 7402353. DOI: 10.3390/ijms21144883.


Cell type-specific mechanisms coupling protease-activated receptor-1 to infectious colitis pathogenesis.

Boucher A, Rosenfeldt L, Mureb D, Shafer J, Sharma B, Lane A J Thromb Haemost. 2019; 18(1):91-103.

PMID: 31539206 PMC: 7026906. DOI: 10.1111/jth.14641.


Protease-activated receptor-1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy.

Waasdorp M, de Rooij D, Florquin S, Duitman J, Spek C J Cell Mol Med. 2018; 23(2):1268-1279.

PMID: 30485646 PMC: 6349177. DOI: 10.1111/jcmm.14028.


References
1.
Gilbane A, Denton C, Holmes A . Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther. 2013; 15(3):215. PMC: 4060542. DOI: 10.1186/ar4230. View

2.
Cevikbas F, Seeliger S, Fastrich M, Hinte H, Metze D, Kempkes C . Role of protease-activated receptors in human skin fibrosis and scleroderma. Exp Dermatol. 2010; 20(1):69-71. DOI: 10.1111/j.1600-0625.2010.01184.x. View

3.
Yamamoto T, Takagawa S, Katayama I, Nishioka K . Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol. 1999; 92(1):6-13. DOI: 10.1006/clim.1999.4720. View

4.
Howell D, Johns R, Lasky J, Shan B, Scotton C, Laurent G . Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol. 2005; 166(5):1353-65. PMC: 1606391. DOI: 10.1016/S0002-9440(10)62354-1. View

5.
Shaw T, Kishi K, Mori R . Wound-associated skin fibrosis: mechanisms and treatments based on modulating the inflammatory response. Endocr Metab Immune Disord Drug Targets. 2010; 10(4):320-30. DOI: 10.2174/1871530311006040320. View